S-14,671

From Wikipedia, the free encyclopedia
S-14,671
Systematic (IUPAC) name
N-{2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl}thiophene-2-carboxamide
Clinical data
Legal status ?
Identifiers
CAS number 135722-27-9
ATC code None
PubChem CID 131907
ChemSpider 116529
Chemical data
Formula C22H25N3O2S 
Mol. mass 395.52 g/mol

S-14,671 is a naphthylpiperazine derivative which acts as a 5-HT1A receptor agonist (pKi = 9.3) with high efficacy and exceptional in vivo potency, and also as a 5-HT2A and 5-HT2C receptor antagonist (both are pKi = 7.8).[1][2] It displays only low and non-significant affinity for 5-HT1B and 5-HT3 sites.[2]

In producing 5-HT1A-mediated effects such as hypothermia and spontaneous tail flicks in rodents, S-14,671 is active at doses as low as 5 µg subcutaneously, and is about 10-fold more potent than 8-OH-DPAT and 100-fold more potent than flesinoxan and buspirone.[1][2] Other 5-HT1A-mediated effects of S-14,671 include induction of flat-body posture, corticosterone secretion, inhibition of morphine-induced antinociception, and attenuation of the electrical activity of the dorsal raphe nucleus.[2]

S-14,671 has been found to possess powerful efficacy in the rodent forced swim test and in the pigeon conflict test, indicating marked antidepressant and anxiolytic effects, respectively, of which are also 5-HT1A-mediated.[3][4] It has never been trialed in humans, perhaps due to its potency being too great.[citation needed]

See also

References

  1. ↑ 1.0 1.1 Millan MJ, Canton H, Rivet JM, Lejeune F, Laubie M, Lavielle G (October 1991). "S 14671: a novel naphthylpiperazine 5-HT1A agonist of high efficacy and exceptional in vivo potency". European Journal of Pharmacology 203 (2): 319–22. doi:10.1016/0014-2999(91)90734-8. PMID 1839284. 
  2. ↑ 2.0 2.1 2.2 2.3 Millan MJ, Rivet JM, Canton H, et al. (August 1992). "S 14671: a naphtylpiperazine 5-hydroxytryptamine1A agonist of exceptional potency and high efficacy possessing antagonist activity at 5-hydroxytryptamine1C/2 receptors". The Journal of Pharmacology and Experimental Therapeutics 262 (2): 451–63. PMID 1323650. 
  3. ↑ Schreiber R, Brocco M, Gobert A, Veiga S, Millan MJ (December 1994). "The potent activity of the 5-HT1A receptor agonists, S 14506 and S 14671, in the rat forced swim test is blocked by novel 5-HT1A receptor antagonists". European Journal of Pharmacology 271 (2-3): 537–41. doi:10.1016/0014-2999(94)90816-8. PMID 7705455. 
  4. ↑ Schreiber R, Brocco M, de Ladonchamps BL, Millan MJ (1995). "Involvement of 5-HT1A receptors in the anxiolytic action of S 14671 in the pigeon conflict test". Pharmacology, Biochemistry, and Behavior 51 (2-3): 211–5. doi:10.1016/0091-3057(94)00421-E. PMID 7667330. 
Anxiolytics (N05B)
GABAA
PAMs
non-N05B
α2δ VDCC Blockers
5-HT1A Agonists
H1 Antagonists
CRH1 Antagonists
NK2 Antagonists
MCH1 antagonists
mGluR2/3 Agonists
mGluR5 NAMs
TSPO agonists
σ1 agonists
Antidepressants
Others

M: PSO/PSI

mepr

dsrd (o, p, m, p, a, d, s), sysi/epon, spvo

proc (eval/thrp), drug (N5A/5B/5C/6A/6B/6D)

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.